1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
North America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action

North America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action

  • November 2022
  • 193 pages
  • ID: 6368986
  • Format: PDF
  • The Insight Partners

Summary

Table of Contents

Search Inside

The glycomic therapeutics market in North America is expected to grow from US$ 42,552.69 million in 2022 to US$ 1,00,790.58 million by 2028; it is estimated to grow at a CAGR of 15.5% from 2022 to 2028.

Application in Treatment of Broad Range of Disorders Drives Market Growth

Glycan-based products have wide applications in the therapeutic industry; the products are available in different structures & forms and developed as per the application.This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, and anti-inflammation.

The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells.Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are a part of several research projects.

These products are aimed at expanding and improving their applicability and efficacy.EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer’s disease in rodent models due to its known neuroprotective effects.

The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions.

For instance, in April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule, only found in cancer cells. The researchers have claimed that the protein might revolutionize cancer detection.

In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform.The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study.

Merck, a CQDM member, is financing the study.The University of Alberta and 48HD will work together on the project.

Additionally, GlycoNet, a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, is providing the funds to enhance the quality of life of Canadians.

In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes.Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation.

One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD).The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions.

These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the region drives the glycomics therapeutics market.

Market Overview

The North America glycomic therapeutics market is segmented into the US, Canada, and Mexico.The US held the largest share of the North America glycomic therapeutics market in 2022.

The increasing demand in the region, followed by rising research and development activities by various major firms, rising number of investments in glycomic therapeutics research, and growing awareness about glycomic therapeutics, is expected to drive the overall glycomic therapeutics market during the forecast period.

North America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

North America Glycomic Therapeutics Market Segmentation

The North America glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the North America glycomic therapeutics market is bifurcated into isolated and synthetic.The synthetic segment registered a larger market share in 2022.

Based on structure, the North America glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others.The glycoproteins segment held the largest market share in 2022.

Based on indications, the North America glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, Alzheimer’s disease, influenza type A & B, and others.The influenza type a & b segment held the largest market share in 2022.

Based on mode of action, the North America glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); HalozymeTherapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Lt. are the leading companies operating in the glycomic therapeutics in North America.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Asia-Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action

  • $ 3000
  • November 2022
  • 210 pages

The glycomic therapeutics market in Asia Pacific is expected to grow from US$ 12,950.82 million in 2022 to US$ 34,592.83 million by 2028; it is estimated to grow at a CAGR of 17.8% from 2022 to 2028. Wide ...

  • APAC
  • Therapy
  • Genomics
  • Industry analysis
  • Cancer Incidence
  • Health Expenditure

ref:plp2022

Reportlinker.com © Copyright 2023. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on